Journal
VIROLOGY
Volume 477, Issue -, Pages 1-9Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2014.12.037
Keywords
HCV; NS5B; Pyrosequencing; Drug resistance mutation; In silica molecular modeling
Categories
Funding
- Ontario HIV Treatment Network, Canada [ROGB171]
- Public Health Agency of Canada
Ask authors/readers for more resources
Identifying HCV drug resistance mutations (DRMs) is increasingly important as new direct acting antiviral therapies (DAA) become available. Tagged pooled pyrosequencing (TPP) was originally developed as cost-effective approach for detecting low abundance HIV DRMs. Using 127 HCV-positive samples from a Canadian injection drug user cohort, we demonstrated the suitability and efficiency of TPP for evaluating DRMs in HCV NS5B gene. At a mutation identification threshold of 1%, no nucleoside inhibitor DRMs were detected among these DAA naive subjects. Clinical NS5B resistance to non-nucleoside inhibitors and interferon/ribavirin was predicted to be low within this cohort. S282T mutation, the primary mutation selected by sofosbuvir in vitro, was not identified while S282G/C/R variants were detected in 9 subjects. Further characterization on these new S282 variants using in silica molecular modeling implied their potential association with resistance. Combining TPP with in silica analysis detects NS5B polymorphisms that may explain differences in treatment outcomes. Crown Copyright (C) 2014 Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available